Evidence map›Paper›PMID 39207101›Full record

ArticlemBio2024

Role of IgA1 protease-producing bacteria in SARS-CoV-2 infection and transmission: a hypothesis.

Michael W Russell, Mogens Kilian, Jiri Mestecky

Abstract read
In one paragraph

Article in mBio, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed.

  1. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

3 authors.

Michael W RussellDepartment of Microbiology and Immunology, Jacobs School of Medicine and Biomedical Sciences, University at Buffalo, Buffalo, New York, USA.ORCID 0000-0002-1303-4061
Mogens KilianDepartment of Biomedicine, Aarhus University, Aarhus, Denmark.ORCID 0000-0002-5861-0472
Jiri MesteckyDepartment of Microbiology, Heersink School of Medicine, University of Alabama at Birmingham, Birmingham, Alabama, USA.ORCID 0000-0001-8133-2119

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Secretory (S) IgA antibodies against severe acute respiratory syndrome (SARS)-CoV-2 are induced in saliva and upper respiratory tract (URT) secretions by natural infection and may be critical in determining the outcome of initial infection. Secretory IgA1 (SIgA1) is the predominant isotype of antibodies in these secretions. Neutralization of SARS-CoV-2 is most effectively accomplished by polymeric antibodies such as SIgA. We hypothesize that cleavage of SIgA1 antibodies against SARS-CoV-2 by unique bacterial IgA1 proteases to univalent Fabα antibody fragments with diminished virus neutralizing activity would facilitate the descent of the virus into the lungs to cause serious disease and also enhance its airborne transmission to others. Recent studies of the nasopharyngeal microbiota of patients with SARS-CoV-2 infection have revealed significant increases in the proportions of IgA1 protease-producing bacteria in comparison with healthy subjects. Similar considerations might apply also to other respiratory viral infections including influenza, possibly explaining the original attribution of influenza to

Indexed as

COVID-19Immunoglobulin A, SecretorySARS-CoV-2Antibodies, NeutralizingAntibodies, ViralBacteriaHaemophilus influenzaeHumansImmunoglobulin ANasopharynxSerine EndopeptidasesAntibodies, NeutralizingAntibodies, ViralIgA-specific serine endopeptidaseImmunoglobulin AImmunoglobulin A, SecretorySerine Endopeptidasesbacterial IgA1 proteaseCOVID-19immunoglobulin Amucosal immunitySARS-CoV-2

Identifiers

PMID39207101
PMCPMC11492985

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.